Skip to main content
Clinical Trials/NCT05031832
NCT05031832
Completed
Not Applicable

The Interrelationship Between Chemsex Engagement and HIV Biomedical Prevention in MSM

Chinese University of Hong Kong1 site in 1 country733 target enrollmentStarted: June 1, 2021Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
733
Locations
1
Primary Endpoint
pre-exposure prophylaxis coverage

Overview

Brief Summary

HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.

Study Design

Study Type
Observational
Observational Model
Ecologic Or Community
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • aged 18 or above
  • have had sex with men since 2019
  • could be communicated in English or Chinese

Exclusion Criteria

  • failed to provide consent

Outcomes

Primary Outcomes

pre-exposure prophylaxis coverage

Time Frame: 6 months

proportion of HIV-negative MSM taking pre-exposure prophylaxis; based on self-reported data in questionnaire

Good antiretroviral therapy adherence

Time Frame: 2 years

proportion of HIV-positive MSM with good antiretroviral therapy adherence; based on self-reported data (CD4 count, viral load level, history of stoppoing ART / missing doses) in questionnaire

Drug use pattern

Time Frame: 6 months

types of drugs taken for chemsex engagement (taking before or during sex); based on self-reported data in questionnaire

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ngai Sze WONG

Assistant Professor

Chinese University of Hong Kong

Study Sites (1)

Loading locations...

Similar Trials